MRK Merck & Co.
Charge-depressed earnings hide a solid franchise, but the price still assumes the Keytruda handoff goes smoothly.
The story
Merck is a scaled, cash-rich pharma whose earnings still lean heavily on Keytruda, which faces US exclusivity loss around 2028. Subcutaneous Keytruda (Qlex), Winrevair, Capvaxive, and bought-in assets such as Ohtuvayre (Verona) and Cidara's flu antiviral are meant to bridge the cliff, and Gardasil's China weakness is a known drag. It is a mature franchise that must replace a giant, using acquisitions as R&D.
I kept all drivers unchanged. The TTM operating margin of about 10% comes from one-time acquired IPR&D charges on the Verona and Cidara deals and does not reflect a change in operating economics, so I still normalize to 33% over 3 years. Revenue is growing about 3.6%, which supports 4% in year 1. The TTM sales-to-capital of 0.66 is low because of those acquisitions, and I treat 1.0 as the sustainable blend of internal R&D plus business development spending over a cycle.
Value drivers
| Revenue growth (Y1) | 4.0% |
| Terminal growth | 2.5% |
| Forecast horizon | 8y |
| Target operating margin | 33.0% |
| Years to target margin | 3 |
| Sales-to-capital | 1.00 |
| Beta | 0.85 |
| Failure probability | 1.0% |
| Cost of capital (WACC) | 8.7% |
| Terminal WACC | 9.3% |
Valuation bridge
| PV of explicit FCFF | 97.76B |
| PV of terminal value | 139.79B |
| Equity value | 200.69B |
| ÷ shares → per share | $81.41 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 70.07B | 4.0% | 17.7% | 10.72B | 2.70B | 8.03B | 7.38B |
| 2 | 72.73B | 3.8% | 25.3% | 15.97B | 2.65B | 13.31B | 11.26B |
| 3 | 75.32B | 3.6% | 33.0% | 21.55B | 2.60B | 18.95B | 14.74B |
| 4 | 77.85B | 3.4% | 33.0% | 22.27B | 2.53B | 19.74B | 14.12B |
| 5 | 80.30B | 3.1% | 33.0% | 22.97B | 2.45B | 20.52B | 13.50B |
| 6 | 82.65B | 2.9% | 33.0% | 23.64B | 2.35B | 21.29B | 12.87B |
| 7 | 84.89B | 2.7% | 33.0% | 24.29B | 2.24B | 22.04B | 12.26B |
| 8 | 87.02B | 2.5% | 33.0% | 24.89B | 2.12B | 22.77B | 11.64B |
Key risks
- Keytruda 2028 LOE erosion outpaces subQ conversion and new launches
- IRA price negotiation and MFN pricing pressure on key US franchises
- Expensive M&A to fill the gap destroys value (overpaying for pipeline)
Catalysts
- Keytruda Qlex subQ adoption rates ahead of the 2028 LOE
- Winrevair label expansion and Phase 3 readouts from acquired assets (Cidara MK-1654 flu, Verona)